HKSH Medical Group and UCLA Health signed a Development Agreement

HistoSonics Announces $100 Million in Financings and New Appointment to its Board of Directors

HistoSonics Announces FDA Approval of its Pivotal IDE #HOPE4KIDNEY Trial

SONIRE Announces First Patient Enrolled in Randomized Phase 2 Study of Its Novel HIFU Therapy System for Unresectable Pancreatic Cancer Patients in Japan

Cadonilimab (PD-1/CTLA-4) Phase III Data for First Line Treatment of Advanced Gastric Cancer Published in Nature Medicine

HONG KONG, Jan. 23, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company")

Asieris Enrolled First Patient for its Phase II Clinical Study of Oral APL-1202 in Combination with Tislelizumab, a PD-1 inhibitor, as Neoadjuvant Therapy for Muscle Invasive Bladder Cancer

HKSH Symposium on Advances in Cancer Management 2024 Breakthroughs in Cancer Management

HONG KONG, Jan. 2, 2025 /PRNewswire/ -- HKSH Cancer Centre organised the sixth "HKSH Symposium on

Dignitana enters Hong Kong market with leading distributor Science International Corporation

Burning Rock Received FDA Breakthrough Device Designation for its OverC™ Multi-Cancer Detection Blood Test